⌘K
Loading ticker…
As of 2026-08-24, Atrium Therapeutics, Inc. Common Stock (RNA) has a 3-month relative strength percentile of 56 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 34. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 3.7%, relative volume 0.70×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Daily range, ATR, beta, and the math for a 1-ADR stop.
Diluted EPS, last 8 quarters. Positive EPS uses YoY change.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
TTM operating margin. Expansion = real operating leverage.
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
RNA is held by 16 ETFs as of May 2026. Top owner: SCHA at 0.00% weight, $879K notional. Top 3 carry $2M.
Held by 34 ETFs · $21M across latest filings · largest weight 0.48% (JSML).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| SCHASchwab U.S. Small-Cap ETF | 0.00% | $879K | — |
| VTWO | 0.00% | $818K | — |
| VTWG | 0.01% | $137K | — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $107K | — |
| ESGV | 0.00% | $33K | — |
| SCHK | 0.00% | $14K | — |
| VTHRVanguard Russell 3000 ETF | 0.00% | $12K | — |
| VTWV | 0.00% | $9K | — |
| ITWO | 0.00% | $7K | — |
| MSSM | 0.00% | $6K | — |
Showing 10 of 16 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RNA Jan avg: 13.95% median: 10.02% win: 100% σ: 15.04% n: 4 2022-04-12 → 2026-07-31 | RNA Feb avg: -9.25% median: -3.48% win: 25% σ: 53.28% n: 4 2022-04-12 → 2026-07-31 | RNA Mar avg: -2.20% median: -6.51% win: 25% σ: 30.98% n: 4 2022-04-12 → 2026-07-31 | RNA Apr avg: -8.42% median: -5.45% win: 20% σ: 13.53% n: 5 2022-04-12 → 2026-07-31 | RNA May avg: -1.79% median: -2.59% win: 40% σ: 9.41% n: 5 2022-04-12 → 2026-07-31 | RNA Jun avg: 11.19% median: 4.31% win: 80% σ: 23.48% n: 5 2022-04-12 → 2026-07-31 | RNA Jul avg: 4.62% median: 11.58% win: 60% σ: 19.22% n: 5 2022-04-12 → 2026-07-31 | RNA Aug avg: 5.84% median: 8.49% win: 50% σ: 21.88% n: 4 2022-04-12 → 2026-07-31 (current) | RNA Sep avg: -8.61% median: -11.04% win: 25% σ: 9.82% n: 4 2022-04-12 → 2026-07-31 | RNA Oct avg: 5.12% median: -10.27% win: 25% σ: 37.09% n: 4 2022-04-12 → 2026-07-31 | RNA Nov avg: 9.41% median: 2.23% win: 75% σ: 29.81% n: 4 2022-04-12 → 2026-07-31 | RNA Dec avg: 18.67% median: 8.24% win: 75% σ: 52.04% n: 4 2022-04-12 → 2026-07-31 |